Lifecore Biomedical vs Maravai LifeSciences
LFCR and MRVI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LFCR and MRVI compare
Maravai LifeSciences is the larger company, worth 8.1 times as much as Lifecore Biomedical ($2.0B against $243M).
Maravai LifeSciences grew revenue faster over the last twelve months (10.7% versus 0.47% for Lifecore Biomedical).
Lifecore Biomedical keeps more of each dollar of sales as profit, with a net margin of −30.0% compared with −30.8% at Maravai LifeSciences.
Maravai LifeSciences scores higher on the StockData Score (8 against 4 for Lifecore Biomedical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LFCR | MRVI |
|---|---|---|
| Size and price | ||
| Market cap | $243M | $2.0B |
| Share price | $6.42 | $7.54 |
| Change, 1 year | −21.9% | 132% |
| Change, 5 years | −32.3% | −79.9% |
| Beta (5Y) | 1.04 | 1.01 |
| Employees | 382 | 435 |
| StockData Score | ||
| Total score | 4 | 8 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 3 (better) |
| Performance score | 2 | 2 |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.9× (better) | 9.2× |
| P/B | – | 10.0× |
| FCF yield | −5.6% | −0.68% (better) |
| Fair value | – | $2.60 |
| Margin of safety | – | −190% |
| Growth | ||
| Revenue growth (TTM) | 0.47% | 10.7% (better) |
| Revenue growth, 5Y average | −4.2% (better) | −8.1% |
| Net income growth (TTM) | −422% | – |
| EPS growth (TTM) | −485% | – |
| Profitability | ||
| Gross margin | 31.3% | 39.1% (better) |
| Operating margin | −13.4% (better) | −45.4% |
| Net margin | −30.0% (better) | −30.8% |
| FCF margin | −10.6% | −6.2% (better) |
| Return on equity | – | −29.8% |
| Return on invested capital | – | −27.0% |
| Financial health | ||
| Debt / equity | – | 0.75 |
| Interest coverage | −0.8× (better) | −4.6× |
| Current ratio | 3.84 | 4.66 (better) |
| Altman Z-score | −0.52 | 4.54 (better) |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −9.8% | – |
| Shareholder yield | −9.8% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 67.1% | 55.5% |
| Held by insiders | 46.1% | 3.6% |
| Insider net buying, 12 months | – | $115K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 8.4% | 5.6% |
Go deeper
- LFCR stock overview
- LFCR income statement
- LFCR valuation and score
- MRVI stock overview
- MRVI income statement
- MRVI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.